Corneal R&D that will reduce the 13m global patient list.

Kerato utilises multi-patented technology with world-class expertise in tissue engineering and biomaterials to develop bio-equivalent corneal tissue that reproduces the complex structure and function of human and animal tissue.

Kerato provides innovative solutions that address medical challenges through their portfolio of Regenerative Therapies; and bioequivalent, scaffold-free tissue for commercial R&D applications.

Corneas are the most frequently transplanted human tissue, however there is a shortage of suitable donor material. There are a lack of effective veterinary interventions to treat corneal damage.

Corneal regenerative therapies

Kerato’s first product is a Biosynthetic Cornea. 

A single-use device designed for single-handed administration in a variety of clinical settings.

Effective treatment of corneal damage using the device reduces the need for corneal transplants by supporting tissue repair.

Introducing

Kerato

Treatment of corneal tissue damage.

Global

Impact

Addressing corneal tissue shortages.

Addressing the global shortage of donor corneal tissue by providing a biosynthetic treatment alternative.

Effective early intervention.

Providing effective early interventions for the treatment of corneal damage caused through injury or disease.

Reducing animal cruelty.

Reducing reliance on animal models in commercial R&D settings.

Global

Impact

Timeline

Supporting commercial R&D of scaffold-free tissues.

2024

Following completion of our veterinary trials, we aim to launch our product on to veterinary markets in late 2025.

2025

We are working with clinicians, hospitals and patient groups to design clinical studies that will benefit patients and support regulatory approvals.

2026

Following regulatory approval, we will launch our medical device to the market.

2029

Corneal industry

Facts

Vision impairment is an increasing public health concern, impacting physical, cognitive and mental health (WHO, 2023).

The ophthalmic veterinary market is growing, and there is an increasing demand for sutiable treatments.

Access to donor corneal tissue is not universal, and 55% of the global population do not have access to suitable material for transplants.